ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

This study has been terminated.

Sponsored by: Enzon Pharmaceuticals, Inc.
Information provided by: Enzon Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00023166
  Purpose

Studies of PEG-paclitaxel have been terminated


Condition Intervention Phase
Neoplasm
Lymphomas
Neoplasm Metastasis
Drug: PEG-paclitaxel
Phase I

MedlinePlus related topics:   Cancer    Lymphoma   

Drug Information available for:   Paclitaxel   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:   Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas

Further study details as provided by Enzon Pharmaceuticals, Inc.:

Study Start Date:   May 2001
Estimated Study Completion Date:   May 2002

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

None - Study has been terminated.

  Contacts and Locations

No Contacts or Locations Provided
  More Information


Study ID Numbers:   PTX-5001
First Received:   August 24, 2001
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00023166
Health Authority:   United States: Food and Drug Administration

Keywords provided by Enzon Pharmaceuticals, Inc.:
Phase I  
Open label  
Safety/efficacy  
Lymphomas  
Advanced primary and/or metastatic solid tumors
Neoplasms
Neoplasm metastasis

Study placed in the following topic categories:
Lymphatic Diseases
Immunoproliferative Disorders
Paclitaxel
Neoplasm Metastasis
Lymphoproliferative Disorders
Lymphoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Mitosis Modulators
Antimitotic Agents
Pharmacologic Actions
Neoplasms
Neoplastic Processes
Pathologic Processes
Therapeutic Uses
Tubulin Modulators
Antineoplastic Agents, Phytogenic

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers